Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus NEBUPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus NEBUPENT.
ATOVAQUONE vs NEBUPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
Nebupent (pentamidine isethionate) is an antimicrobial agent that inhibits the synthesis of DNA, RNA, phospholipids, and proteins in protozoa. Its mechanism may involve interference with polyamine synthesis and inhibition of dihydrofolate reductase.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
300 mg via inhalation once every 4 weeks for prophylaxis of Pneumocystis jirovecii pneumonia.
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
Clinical Note
moderateAtovaquone + Dapsone
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
Terminal elimination half-life: 6-9 hours (prolonged in renal impairment; clinical context: supports once-daily dosing for treatment, but prophylaxis may require reduced frequency in renal dysfunction)
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<5%)
Category A/B
Category C
Antiprotozoal
Antiprotozoal, Inhaled
"The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone."